Newsroom.csl.com

News Releases CSL

WEBThe World Health Organization (WHO) estimates that seasonal influenza results in up to 650,000 respiratory deaths each year. 1 In the U.S. specifically, influenza …

Actived: 1 days ago

URL: https://newsroom.csl.com/2022-09-26-New-Data-at-OPTIONS-XI-Conference-Highlight-Burden-of-Seasonal-Influenza-on-Health-Systems-and-the-Need-for-Increased-Vaccination-Rates

CSL Behring Announces the First Patient Has Received FDA …

WEBHEMGENIX ®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce …

Category: Health Go Health

CSL's HOPE-B Data Published in the New England Journal of …

WEBResults from the HOPE-B trial, the largest gene therapy study in hemophilia B to date, were considered by the authors to demonstrate that HEMGENIX ® is superior …

Category: Health Go Health

News Releases CSL

WEBSummit, NJ, USA 07 Feb 2022. Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new …

Category: Health Go Health

CSL Opens New, State-of-the-Art Vaccine Research and …

WEBThe site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines . WALTHAM, Mass., …

Category: Health Go Health

News Releases CSL

WEBMELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 / PRNewswire / -- At its annual R&D investor briefing today, global biotechnology leader …

Category: Health Go Health

CSL's Novel Gene Therapy HEMGENIX® (etranacogene …

WEB"Gene therapy has great potential for rare bleeding disorders, and these results demonstrate long-lasting increases in factor IX activity levels, reaching levels …

Category: Health Go Health

News Releases CSL

WEBCSL (ASX: CSL) (USOTC:CSLLY) is a global biotechnology company with a portfolio covering haemophilia and immune deficiencies, vaccines to prevent influenza, …

Category: Health Go Health

CSL Seqirus Shares Data Demonstrating the Potential for Influenza

WEBCSL Seqirus presents new data at the 9 th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world. 1, 2; …

Category: Health Go Health

News Releases CSL

WEBMini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build “Australia’s next CSL”. Australia’s newest biotech incubator Jumar …

Category: Health Go Health

News Releases CSL

WEBCSL Seqirus. (+61) 422 424 338. [email protected]. About CSL Seqirus. CSL Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine …

Category: Health Go Health

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) …

WEBHEMGENIX ® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained …

Category: Food Go Health

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial

WEBKING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS …

Category: Health Go Health

New COVID-19 sa-mRNA Results from CSL and Arcturus …

WEBThe new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain …

Category: Health Go Health

Biotech Leader CSL Again Named Among America's Best …

WEBCSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 / …

Category: Health Go Health

Swissmedic Authorises CSL's HEMGENIX® (etranacogene …

WEBCSL's HEMGENIX ® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B. BERN, Switzerland, Jan. 15, 2024 …

Category: Health Go Health